▲ +1.70% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Nevro in the last 3 months. The average price target is $178.92, with a high forecast of $215.00 and a low forecast of $100.00. The average price target represents a 1.70% upside from the last price of $175.93.
The current consensus among 13 polled investment analysts is to buy stock in Nevro. This Buy consensus rating has held steady for over two years.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.